For the year ended 31 March, net profit dropped to Y8.45bn from Y9.94bn, while revenue rose to Y89.16bn from Y87.31bn.
Operating profit edged up to Y12.37bn from Y12.20bn, but pretax profit fell to Y11.04bn from Y12.84bn and earnings per share declined to Y191.80 from Y225.42.
The Japanese drugmaker reported the results under Japanese accounting standards, showing higher sales but weaker bottom-line performance over the fiscal year.
As global sales rise while profits fall, can Zeria's international push outpace Japan's relentless price cuts?
With rivals pushing advanced biologics, is Zeria’s strategy of reformulating older drugs a winning long-term plan?